A panel of 19 monoclonal antibodies (MAbs) were used to probe the antigenic relationships between the G (attachment) proteins of A and B respiratory syncytial virus (RSV) subtypes (G A and GB). At least three and two antigenic sites were present on G A and Gs, respectively, including a shared neutralizing site. Most of the antibodies had some degree of complement-independent neutralizing capacity, but in common was a large neutralization-resistant fraction of virus (range 13 to 789/o). Passive administration of MAbs to the cross-reactive antigenic site reduced pulmonary virus titres of both A and B subtype virus in the cotton rat model. Protection with subtypespecific MAbs, however, did not always correlate with in vitro neutralizing capacity. The cross-reactive antigenic site appears to be stable to denaturation by polyacrylamide gel electrophoresis and is present on the unglycosylated and partially glycosylated forms of GA and GB by Western blot analysis of infected cell lysates.
INTRODUCTION
Respiratory syncytial virus (RSV), a negative-strand RNA virus of the paramyxovirus family, is the leading cause of severe lower respiratory tract infection in infants (Kim et al., 1973) . The viral genome encodes 10 proteins including two envelope glycoproteins which subserve attachment and penetration functions . The attachment protein (G) has a protein backbone of 298 amino acids with an Mr of 32K but migrates by PAGE with an Mr of 84K to 90K because of extensive O-linked and N-linked glycosylation Levine et al., 1987) . Viral penetration into cells and cell-to-cell spread of virus is mediated by the 70K fusion protein (F), a typical paramyxovirus fusion protein composed of disulphide-linked fragments, F1 (48K) and FE (23K) (Walsh & Hruska, 1983) . Neutralizing epitopes are present on both F and G proteins and, thus, are candidates for use in a subunit RSV vaccine (Walsh & Hruska, 1983; Walsh et al., 1984) . Immunization of cotton rats with purified F or G protein confers protection from challenge with RSV (Walsh et al., 1987a) .
Recently, two antigenically distinct subtypes of RSV, designated A and B, have been described independently from several laboratories (Anderson et al., 1985; Mufson et al., 1985; Storch & Park, 1987) . Both antigenic and structural differences between subtypes have been described for several RSV proteins, including G and F (Ward et al., 1984; Norrby et al., 1986; Walsh et al., 1987b; Morgan et al., 1987) . The most significant antigenic difference between A and B subtypes, however, resides on the G protein where amino acid homology is only 53 % and antigenic relatedness is 5% Johnson et al., 1987a) . Mufson et al. (1985) reported that only one of six monoclonal antibody (MAb)-defined epitopes on G was present on RSV isolates of both subtypes. Additionally, convalescent human antisera and rabbit polyclonal 0000-8918 © 1989 SGM antisera to afffinity-purified G from either subtype has little cross-reactivity, and neutralization is essentially subtype-specific Johnson et al., 1987b; Hendry et al., 1988) . Consistent with these findings, immunization of cotton rats with a vaccinia virus vector expressing A subtype G (GA) provided primarily subtype specific protection (Stott et al., 1987; Johnson et al., 1987b) . In contrast, the F protein has a high degree of structural and antigenic homology between subtypes (Johnson & Collins, 1988) . Thus it has been suggested that an optimal subunit RSV vaccine should contain G proteins representing both RSV subtypes and a single F protein.
In order to explore further the antigenic relationship and identify neutralizing epitopes on the G proteins, we analysed purified G protein from A and B subtypes (G g and Ga) with a panel of MAbs. The results have identified a single neutralizing protective site, common to the G protein of both A and B subtypes.
METHODS
Virus and cells. HEp-2 cells were maintained in minimal essential medium (MEM) supplemented with 5 % foetal calf serum (FCS), 1 mM-glutamine, penicillin and streptomycin. The Long and 18357 strains of RSV, laboratory prototypes of A and B subtypes respectively, were grown in HEp-2 cells and frozen at -70 °C until use.
Purification of Gproteins. The G proteins from Long and 18537 virus, designated G~ and GB respectively, were purified by immunoaffinity chromatography as previously reported (Walsh et al., 1984 .
Production of MAbs. Eleven MAbs were produced by two intraperitoneal immunizations of BALB/c mice with l0 ~tg of purified G a with Freund's adjuvant, followed by fusion of spleen cells with X63/Ag8.653 myeloma cells as previously described (Walsh & Hruska, 1983) . These MAbs are designated with the prefix C. In a similar fashion, six MAbs to GA were produced and are designated with the prefix K. Two previously described MAbs (L7 and L9), produced by intranasal immunization with live Long RSV, were also used (Walsh & Hruska, 1983) . All hybridomas were screened by indirect immunofluorescent assay (IFA) on infected HEp-2 cells (utilizing the homologous strain) and further characterized by enzyme immunoassay (EIA) and Western blotting against RSV proteins. Immunoglobulin type and subtype were identified by Ouchterlony double diffusion with mouse subtypespecific antisera (Meloy and Litton Bionetics). The concentration of MAb in ascites was determined by electrophoresis on cellulose acetate membranes, followed by scanning densitometry.
Virus neutralization. Neutralization of Long and 18537 RSV was performed by a plaque reduction assay. Briefly, 50 to 100 p.f.u, of virus were mixed with MAb (ascites for all MAbs except K5 and K9 in which ammonium sulphate-precipitated cell culture supernatant was used) for 30 rain and then plaqued on monolayers of HEp-2 cells in 24-well plates. Neutralization was recorded as percentage plaque reduction compared to a control MAb (anti-17D yellow fever virus E protein). Complement was not added to the antibod~virus mixture.
PAGE and Western blots. PAGE and Western blots were performed as previously described using infected HEp-2 cell lysates as the antigen (Walsh et aL, 1984) .
Competitive binding assay (CBA) . MAbs were ammonium sulphate-precipitated from mouse ascites and labelled with biotin according to a published method (Wagener et al., 1983) . Purified GA or GB in bicarbonate buffer (pH 9.6) was absorbed to EIA plates (Dynatech Immunlon-2) at 25 ng/well overnight at 4 °C. The wells were washed with phosphate-buffered saline (PBS) and then incubated for 2 h with predetermined concentrations of biotinylated MAbs and an excess of unlabefied competitor MAbs (50 Ixg) in PBS-0-5 M-NaC1-2~o horse serum. MAb-binding avidity studies were initially performed and the concentration of unlabelled competitor ensured that epitope saturation was maximal. The plates were washed, and horseradish peroxidase (HRPO)-avidin was added for 1 h, followed by substrate. Plates were read using a Dynatech MR600 microplate reader. The degree of competition was arbitrarily defined as the following: -, < 25 ~; +, 25 to 60~; +, > 60~; T, > 100~ increased binding.
Animalprotection experiments. Adult cotton rats (100 to 230 g) were anaesthetized with penthrane and injected intraperitoneally with MAb (2 ~tg/g body weight) in groups of four (experimental) or five (control groups). One h later the animals were intranasally infected with 105 p.f.u, of either Long or 18537 RSV. On day 4 the animals were exsanguinated under penthrane anaesthesia, and the lungs removed under sterile conditions, weighed and homogenized in MEM-5 ~o FCS. The homogenates were fast-frozen and stored at -70 °C. Virus titrations were performed on HEp-2 monolayers in quadruplicate and the titres recorded as TCIDso/g lung tissue. Endpoint titres were confirmed by IFA for RSV antigen on the first negative wells.
RESULTS
A total of 19 MAbs were available: six from immunization with GA, 11 by immunization with Ga and two by immunization with live Long RSV. All but three MAbs (L7, L9 and K6) were RSV subtype-specific by indirect immunofluorescence on infected HEp-2 cells or by EIA using purified G in the solid phase (Table 1) . Western blot analysis confirmed that L7, L9 and K6 react with both the Long and 18537 G proteins ( Fig. 1 a to c) . In addition, K8 weakly crossreacted with GB by Western blot, although not by IFA or EIA. Differing patterns of reactivity to the G proteins were evident by Western blot using infected cell lysates as the antigen. Electrophoresis of both intrinsically radiolabelled and purified G protein has revealed multiple low Mr bands ranging from 32K to 50K representing the protein backbone (G 32) and partially glycosylated forms of G (G45-50) which electrophorese in a ladderlike pattern (Lambert, 1988; Fernie et al., 1983) . MAbs K1, K2, K5 and K9 reacted almost exclusively with the fully glycosylated form of G (G90), while K6, K8, L7 and L9 also reacted relatively strongly with smaller forms of G. The Mr values of these bands ranged between 25K and 50K and probably represent partially glycosylated forms of G, as described above. Among the GB-specific MAbs, C1, C4, C11 and C14 had an identical pattern and reacted more strongly with G32 than with G9o. C6 and C8 reacted almost exclusively with Gg0, as did K8, and the remaining MAbs reacted at least weakly with the partially glycosylated precursors as well as with G90. L7 reacted strongly with many forms of GB, similar to its reactivity with GA.
The results of neutralization tests performed by plaque reduction assays with 1 : 50 dilutions ot MAb without complement added, are shown in Table 1 . At least 50~ neutralization of Long RSV was noted for L7, L9, K2, K6 and K8. With all MAbs tested, a sizeable, persistent, non. neutralizable fraction remained even at very low dilutions of MAbs. This is distinctly differenl from our experience with MAbs to F protein in which nearly complete neutralization at low MAb dilutions is the rule (unpublished observation). This partial neutralization persisted at all dilutions up to 1:1600 for each of the indicated MAbs (Table 1) , except K2 which neutralized only at the lowest dilution tested. K 1, K5 and K9 also neutralized Long RSV, although to a much more limited extent. Some degree of neutralization of 18537 RSV was noted for C1, C3, C4, C7; C8, C10, C12 and C13 and, similar to Long RSV, consistently left a sizeable non-neutralized fraction. Most significant was that L7, L9 and K6, the three MAbs cross-reactive by EIA, IFA and Western blot, neutralized both the Long and 18537 RSV strains well.
Competitive binding studies were then performed to determine epitope specificity of the MAbs on GA and G~. Unfortunately, biotinylation altered binding of some of the MAbs and.
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(a) C12 K1 K 2 K 5 K 6 K 8 K 9 L7 L9 Table 2 . At least three non-overlapping antigenic sites on GA were defined (designated A1, A2 and A3). Four of the MAbs neutralizing the Long strain most (L7, L9, K6, and K8) recognize a single antigenic site on GA (A1), whereas K2 recognizes a separate site (A2). K1, K5 and K9, although not successfully biotinylated, probably bind to at least one other distinct antigenic site (A3) since they do not compete with any of the biotin-labelled MAbs.
Antigenic sites on RSV G proteins
Results of binding studies with Ga are shown in Table 3 . The three MAbs that cross-react by IFA, neutralization and Western blot (L7, L9 and K6) also bind to a single site on GB (designated site B1), similar to their reactivity with GA. Overlapping this antigenic site is a group of four GB-specific MAbs (C7, C10, C12 and C13) which compete bidirectionally with L7, L9 and K6 on GB. MAb C3 is also associated with this site but, paradoxically, enhances the binding of L7, L9 and K6, and interestingly allows K8 binding to GB. K8, which does not bind to GB when incubated alone, also binds to GB in the presence of several other GB-specific MAbs (C1, C4, C6 and C8). Since K8 neutralizes subtype A RSV (Long strain) relatively well (48% at 1 : 1600 dilution), it was of interest to determine whether C3, a weak neutralizer of strain 18537 (24%), or C4, a better neutralizer (70%), would synergistically neutralize 18537 RSV when combined with K8. Experiments confirmed that mixtures of C3 and K8 resulted in enhanced neutralization of 18537 RSV (Fig. 2) but only slight enhancement of C4 neutralization was noted. The correlation between enhanced binding and enhanced neutralization was not always true, since minimal synergistic neutralization of 18537 RSV was noted when the nonneutralizing MAb C6 was mixed with K8, despite the fact that C6 also permitted binding of K8 to GB in the solid-phase assay. Unfortunately, biotinylated MAbs C1, C4, C6, C8, Cll and C14 did not bind to GB sufficiently well to perform competition studies and thus the exact number of other antigenic sites present on GB cannot be definitely determined. However, the Western blot patterns of C 1, C4, C11 and C14 (reacting principally with G3z ) and C6 and C8 (which react principally with G9o ) suggest that two additional antigenic sites may be present.
In order to determine whether the cross-reactive neutralizing MAbs provided protection from challenge with both RSV subtypes, cotton rat protection studies were performed. Passive administration of L7, L9, K6 and K8 provided significant pulmonary protection from challenge with Long RSV, whereas K9 (a weak neutralizer) and K2 (a neutralizer only at high concentration) did not confer resistance (Fig. 3a) . Of note, L7, L9 and K6 also provided significant pulmonary protection from 18537 RSV challenge (Fig. 3b) . In addition, all of the GBspecific MAbs tested significantly reduced 18537 RSV replication. In this case, protection was not related to neutralizing capacity in vitro since a non-neutralizer (C 14) also reduced lung virus titres. Therefore, it may protect animals by complement-enhanced neutralization or by antibody-dependent cell-mediated cytotoxicity, as has been demonstrated in MAb-induced passive protection in mice (Taylor et al., 1984) . In an attempt to extend the in vitro synergistic neutralization by C4 and K8 to the animal model, cotton rats were passively administered C4 alone, K8 alone, and C4 plus K8 prior to challenge with 18537 RSV. Pulmonary virus titres in animals given K8 were similar to control animals (5.8 loglo compared to 5.6 loglo) and C4 alone markedly reduced viral titres (3.6 log10, P = 0-005). The addition of K8 to C4 significantly reduced pulmonary titres even further (2-2 log~o, P -0.05 compared to C4 alone). These results suggest that a subunit RSV vaccine containing an F protein from either subtype is likely to induce cross-protective immunity. Conversely, the structural and antigenic relatedness of the two subtype G proteins is low. We have previously shown that polyclonal monospecific antibody to purified GA or GB has little cross-reactivity by EIA or Western blot and virtually no cross-neutralizing capacity. Consistent with this, Stott et al. (1987) and Johnson et al. (1987a) noted that vaccinia virus recombinants expressing GA provided significantly less protection in both mice and cotton rats from B subtype virus challenge than from homologous virus challenge.
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In the work presented here, we have explored the antigenic relationships of subtype-specific G proteins in more detail. Of 19 MAbs, all but three were subtype-specific, and at least three unique antigenic sites were present on GA and two on GB. Sites A1 and A2 on GA were both neutralizing sites, and antibody binding to site A1 provided protection in the cotton rat model. MAbs defining both antigenic sites on GB are neutralizing, although not all MAbs directed to these sites neutralized the virus in vitro. Importantly, however, passive administration of both non-neutralizing and neutralizing antibodies directed against these sites did provide in vivo protection.
The most significant finding was of a common cross-neutralizing antigenic site (A1 and B1), and MAbs to this site provided significant cross-protection. This was surprising since polyclonal antibody failed to cross-neutralize virus in vitro and active immunization with vaccinia virus GA results in only marginal cross-protection Stott et aL, 1987; Johnson et al., 1987b) . The epitopes recognized by L7, L9 and K6 appear to be stable under the denaturing effects of SDS-PAGE and Western blotting and appear not to be carbohydrate-dependent since antibodies to this site (L7, L9, K6) recognize the partially glycosylated (G 3 2 and G~5-50) forms of the G protein.
The precise locations of antigenic sites A1 and B1 are unknown. Based upon published sequence data, the longest conserved region of GA and GB is a 13 amino acid stretch (residues 164 to 176) in the extracellular portion of the molecule and would be a possible site for the crossreactive epitope (Johnson et al., 1987 a) . Approaches to determine the specific epitope include (i) sequence analysis of site A1 or B1 MAb-resistant mutants, (ii) reactivity of site A1-or B1-specific MAbs with enzymically or chemically derived fragments of GA or GB and (iii) reactivity of these MAbs with synthetic peptides of GA or GB. In a recent report, Norrby et al. (1987) found that sera from animals immunized with A or B subtype RSV reacted with synthetic peptides from multiple regions of G, including a peptide containing part of the conserved region. However, the only subtype cross-reactive MAb tested failed to react with any synthetic peptides.
Another characteristic of site B1 was that site Al-specific MAb binding was enhanced by several GB-specific MAbs, suggesting that this binding site was better exposed under certain conditions. Consistent with this, SDS treatment of GB prior to PAGE allowed K8 to recognize GB on Western blotting, while failing to react by EIA, IFA or neutralization. The biological relevance of this was evident by the synergistic in vitro neutralization and in vivo protection against 18537 RSV by combinations of MAbs.
In conclusion, these data suggest that it may be possible to utilize the common A1/B1 antigenic site to induce a broadly protective immune response to the G protein, which when combined with the F protein may provide the optimal design of an RSV vaccine. However, further work must confirm that this cross-neutralizing, cross-protective antigenic site is present on all RSV strains, since Orvell has demonstrated the existence of antigenic diversity in the G protein of B subtype viruses and has subdivided them into B1 and B2 subgroups (Orvell et al., 1987) .
